<p>Tumors from treated mice were harvested, processed, and tissue sections were stained for the differential expression of CD31 (red) for visualization of endothelial cells (left panels). (D, E, F) Blinded quantitative analysis of CD31 (right panels). Results are expressed as mean percentage positive stained area ± S.E. *<i>p</i><0.05 using adjusted t-test analysis.</p
<p>Mice were treated with vehicle, ziv-aflibercept and/or REGN1035. Tumors were harvested, processed...
<p>(A) The data represent mean tumor volumes ± SEM in 16K-Ad-treated (n = 8) or Null-Ad-treated (n =...
<p>(A, B) Immunohistochemical staining of tumor tissue from HRG<sup>+/+</sup> and HRG<sup>−/−</sup> ...
<p>Mice with established subcutaneous tumors were treated with sunitinib for 4 weeks until tumor tis...
<p>CNE-2 and 5–8F tumors were removed and stained with anti-CD31 antibody. Tumor blood vessels were ...
<p>(A), Left panel, tumor tissue sections derived from control, resveratrol and/or TRAIL treated mic...
<p>Representative immunofluorescent images of tumors from control (A) and rHuEPOα-treated (B) mice. ...
<p>Sections of tumors recovered from mice, untreated control and treated with either HB-19 or 5-FU (...
<p>A549 tumor-bearing mice were treated with rh-endostatin (5 mg/kg, s.c.) for consecutive 7 days wi...
<p>Mice (8 mice/group) were treated with vehicle, sunitinib, or ziv-aflibercept and/or REGN1035. Lef...
<p>(<b>A</b>) Tumor sections labeled with anti-CD31 antibody (red) and anti-vaccinia virus (VV) anti...
<p>(A), (C), (E) Sections from size matched 3LL tumors grown in wild type mice and Rgs2 null mice we...
<p>Immunohistochemical detection of endothelial CD31 (A, D, green) and VEGFR-2 (B, E, red) of microv...
<p>LLC tumor-bearing C57BL6/J mice were systemically treated with control saline or with 2.5 mg/kg/d...
<p>(<b>A</b>) Mice treated with sorafenib (90 mg/kg) or control vehicle (DMSO) were in vivo biotinyl...
<p>Mice were treated with vehicle, ziv-aflibercept and/or REGN1035. Tumors were harvested, processed...
<p>(A) The data represent mean tumor volumes ± SEM in 16K-Ad-treated (n = 8) or Null-Ad-treated (n =...
<p>(A, B) Immunohistochemical staining of tumor tissue from HRG<sup>+/+</sup> and HRG<sup>−/−</sup> ...
<p>Mice with established subcutaneous tumors were treated with sunitinib for 4 weeks until tumor tis...
<p>CNE-2 and 5–8F tumors were removed and stained with anti-CD31 antibody. Tumor blood vessels were ...
<p>(A), Left panel, tumor tissue sections derived from control, resveratrol and/or TRAIL treated mic...
<p>Representative immunofluorescent images of tumors from control (A) and rHuEPOα-treated (B) mice. ...
<p>Sections of tumors recovered from mice, untreated control and treated with either HB-19 or 5-FU (...
<p>A549 tumor-bearing mice were treated with rh-endostatin (5 mg/kg, s.c.) for consecutive 7 days wi...
<p>Mice (8 mice/group) were treated with vehicle, sunitinib, or ziv-aflibercept and/or REGN1035. Lef...
<p>(<b>A</b>) Tumor sections labeled with anti-CD31 antibody (red) and anti-vaccinia virus (VV) anti...
<p>(A), (C), (E) Sections from size matched 3LL tumors grown in wild type mice and Rgs2 null mice we...
<p>Immunohistochemical detection of endothelial CD31 (A, D, green) and VEGFR-2 (B, E, red) of microv...
<p>LLC tumor-bearing C57BL6/J mice were systemically treated with control saline or with 2.5 mg/kg/d...
<p>(<b>A</b>) Mice treated with sorafenib (90 mg/kg) or control vehicle (DMSO) were in vivo biotinyl...
<p>Mice were treated with vehicle, ziv-aflibercept and/or REGN1035. Tumors were harvested, processed...
<p>(A) The data represent mean tumor volumes ± SEM in 16K-Ad-treated (n = 8) or Null-Ad-treated (n =...
<p>(A, B) Immunohistochemical staining of tumor tissue from HRG<sup>+/+</sup> and HRG<sup>−/−</sup> ...